Latest Pharma Insights
ASCO Preview: Top Five Picks From The Abstract Release
The oncology conference promises some significant data readouts across pancreatic, breast and lung cancers, lymphoma, myeloma and more.
Scrip - May 22, 2026
The oncology conference promises some significant data readouts across pancreatic, breast and lung cancers, lymphoma, myeloma and more.
Scrip - May 22, 2026
New Data Show Medtronic’s Altaviva Offers ‘Greater Flexibility’ For Treating Urge Incontinence
Medtronic presented 24-month data from its Altaviva TITAN 2 pivotal study at the 2026 American Urological Association Annual Meeting in DC. Medtronic says Altaviva, a small device implanted just below the skin near the ankle, offers relief for millions with urge urinary incontinence.
Medtech Insight - May 22, 2026
Medtronic presented 24-month data from its Altaviva TITAN 2 pivotal study at the 2026 American Urological Association Annual Meeting in DC. Medtronic says Altaviva, a small device implanted just below the skin near the ankle, offers relief for millions with urge urinary incontinence.
Medtech Insight - May 22, 2026
MiniMed Study Finds Sensor Choice Has Little Impact On Glycemic Outcomes With 780G System
A head-to-head crossover trial and real-world data from more than 20,000 patients point to the same conclusion: in automated insulin delivery, the algorithm matters more than the sensor. MiniMed's 780G system is now backed by mounting evidence – and a fresh Nasdaq listing.
Medtech Insight - May 22, 2026
A head-to-head crossover trial and real-world data from more than 20,000 patients point to the same conclusion: in automated insulin delivery, the algorithm matters more than the sensor. MiniMed's 780G system is now backed by mounting evidence – and a fresh Nasdaq listing.
Medtech Insight - May 22, 2026
MHRA Outlines Plans For Medical Device CE Mark Recognition
At RAPS 2026, the MHRA announced updates on its consultation for indefinite CE Mark recognition and its own version of breakthrough device designation.
HBW Insight - May 22, 2026
At RAPS 2026, the MHRA announced updates on its consultation for indefinite CE Mark recognition and its own version of breakthrough device designation.
HBW Insight - May 22, 2026
Abiomed’s Latest Impella Recall Can’t Be Fixed by Swapping Units
The FDA has issued an early alert on Automated Impella Controllers from Johnson & Johnson subsidiary Abiomed because the devices may suddenly restart. This is the latest in a series of recalls for the heart pump specialists.
Medtech Insight - May 22, 2026
The FDA has issued an early alert on Automated Impella Controllers from Johnson & Johnson subsidiary Abiomed because the devices may suddenly restart. This is the latest in a series of recalls for the heart pump specialists.
Medtech Insight - May 22, 2026
Deal Watch: Quince Moves Into Inhaled Respiratory Disease With Orphai Acquisition
Plus deals involving Incyte/Genesis Molecular AI and Edison Scientific, Jupiter/PharmAla, Abeona/Angeles Therapeutics, Daewoong/Innovo, GSK/CTTQ and more.
Scrip - May 22, 2026
Plus deals involving Incyte/Genesis Molecular AI and Edison Scientific, Jupiter/PharmAla, Abeona/Angeles Therapeutics, Daewoong/Innovo, GSK/CTTQ and more.
Scrip - May 22, 2026
CHMP Endorses Another Ranibizumab For Lupin
At its latest meeting, the EMA’s CHMP has endorsed a further biosimilar ranibizumab rival to Lucentis from Lupin. Meanwhile, Celltrion has withdrawn a filing for an infliximab product.
Generics Bulletin - May 22, 2026
At its latest meeting, the EMA’s CHMP has endorsed a further biosimilar ranibizumab rival to Lucentis from Lupin. Meanwhile, Celltrion has withdrawn a filing for an infliximab product.
Generics Bulletin - May 22, 2026
EMA Decision For Boehringer’s Jascayd Paves Way For New IPF and PPF Treatment In Europe
Jascayd, for treating adults with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, is among eight new medicines that the European Medicines Agency recommended for pan-EU marketing approval this week.
Pink Sheet - May 22, 2026
Jascayd, for treating adults with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, is among eight new medicines that the European Medicines Agency recommended for pan-EU marketing approval this week.
Pink Sheet - May 22, 2026
Bayer Raises Its Cell And Gene Therapy Bet As Others Fold
The sector has seen multiple setbacks, with some big pharmas heading for the exits, but the German major believes its heavy investments in the space will ultimately pay dividends.
Scrip - May 22, 2026
The sector has seen multiple setbacks, with some big pharmas heading for the exits, but the German major believes its heavy investments in the space will ultimately pay dividends.
Scrip - May 22, 2026
Biogen, Denali Discontinue BIIB122 Development In Idiopathic Parkinson’s After Phase IIb Miss
Biogen and Denali’s decision to discontinue BIIB122 in idiopathic Parkinson’s disease after a failed Phase IIb study shifts focus toward genetically defined LRRK2 patient subsets and other late-stage neuroscience pipeline catalysts.
Scrip - May 22, 2026
Biogen and Denali’s decision to discontinue BIIB122 in idiopathic Parkinson’s disease after a failed Phase IIb study shifts focus toward genetically defined LRRK2 patient subsets and other late-stage neuroscience pipeline catalysts.
Scrip - May 22, 2026
People On The Move: Appointments at Cooper, Opella, Chiesi
A round up of the latest people moves: Cooper Consumer Health names Italy head and Iberia marketing lead; Opella appoints people head for Europe and LatAm; and Chiesi elects chair.
HBW Insight - May 22, 2026
A round up of the latest people moves: Cooper Consumer Health names Italy head and Iberia marketing lead; Opella appoints people head for Europe and LatAm; and Chiesi elects chair.
HBW Insight - May 22, 2026
Formycon Launches Pre-Filled Eylea Biosimilars In Europe
With a US launch window locked in for Q4 2026 and Europe already live, Formycon is converting years of development and deal-making into commercial momentum.
Generics Bulletin - May 22, 2026
With a US launch window locked in for Q4 2026 and Europe already live, Formycon is converting years of development and deal-making into commercial momentum.
Generics Bulletin - May 22, 2026
Is AI The Catalyst For Global Biosimilars Development? IQVIA and Kexing Think So
As AI takes center stage, a new extended partnership between Kexing Biopharm and IQVIA is working to further global biosimilars development.
Generics Bulletin - May 22, 2026
As AI takes center stage, a new extended partnership between Kexing Biopharm and IQVIA is working to further global biosimilars development.
Generics Bulletin - May 22, 2026
Sawai Seeks Margin Protection Through Scale And Reliability
Sawai is positioning stable supply, new launches and expanded capacity as profit levers under Japan’s tougher generics pricing regime, even as mature products face pressure.
Generics Bulletin - May 22, 2026
Sawai is positioning stable supply, new launches and expanded capacity as profit levers under Japan’s tougher generics pricing regime, even as mature products face pressure.
Generics Bulletin - May 22, 2026
EU Notified Bodies See A Weakened System While Industry Counts On Timeline Predictability
EU notified bodies will be given maximum turnaround times for medtech file processing once the European Commission’s binding EU implementing regulation comes into force. Notified bodies think it does not give due attention to their place in the care delivery system.
Medtech Insight - May 22, 2026
EU notified bodies will be given maximum turnaround times for medtech file processing once the European Commission’s binding EU implementing regulation comes into force. Notified bodies think it does not give due attention to their place in the care delivery system.
Medtech Insight - May 22, 2026
The 30-Day Bet: Serum Institute Plans Rapid Response To Ebola Outbreak
As Serum Institute aims to get an Oxford-partnered vaccine out at unprecedented speed, the question is whether industry players like Serum, Mapp, Hyundai and others can move faster with vaccines or experimental drugs than Ebola’s Bundibugyo species?
Scrip - May 22, 2026
As Serum Institute aims to get an Oxford-partnered vaccine out at unprecedented speed, the question is whether industry players like Serum, Mapp, Hyundai and others can move faster with vaccines or experimental drugs than Ebola’s Bundibugyo species?
Scrip - May 22, 2026
Personalis Wins Fourth Medicare Coverage For NeXT Personal MRD Test In Neoadjuvant Breast Cancer
Medicare will now reimburse Personalis's ultrasensitive ctDNA test for monitoring treatment response before surgery in Stage II–III triple-negative and HER2-positive breast cancer patients, extending the test's coverage footprint deeper into the treatment pathway.
Medtech Insight - May 22, 2026
Medicare will now reimburse Personalis's ultrasensitive ctDNA test for monitoring treatment response before surgery in Stage II–III triple-negative and HER2-positive breast cancer patients, extending the test's coverage footprint deeper into the treatment pathway.
Medtech Insight - May 22, 2026
ASCO Preview: BioNTech, Innovent/Takeda Vie For Top IO Combo Responses In 1L NSCLC
BioNTech’s pumitamig demonstrated an ORR of 77.3% in first-line NSCLC regardless of PD-L1 status, while Innovent/Takeda’s IBI363 pushed the rate to 86.4% in the non-PD-L1-high population, ASCO abstracts show.
Scrip - May 22, 2026
BioNTech’s pumitamig demonstrated an ORR of 77.3% in first-line NSCLC regardless of PD-L1 status, while Innovent/Takeda’s IBI363 pushed the rate to 86.4% in the non-PD-L1-high population, ASCO abstracts show.
Scrip - May 22, 2026
FDA Will Miss May Allergen Labeling Rule Deadline – OCC Deputy Director
Deputy Director of the US FDA's Office of Cosmetics and Colors provided a MoCRA update during IBA's Spring 2026 Cosmetics Convergence conference in New York May 21.
HBW Insight - May 22, 2026
Deputy Director of the US FDA's Office of Cosmetics and Colors provided a MoCRA update during IBA's Spring 2026 Cosmetics Convergence conference in New York May 21.
HBW Insight - May 22, 2026
US Consumer Health Industry News Digest: Business, Regulation, Science
Weekly digest of US consumer health industry/marketplace news: Congress proposes adding supplements to HSA/FSAs; acting FDA foods program chief familiar to industry; PRE study guidance for formula industry; higher costs not new to industry; and ‘fundamental reset’ in longevity wellness.
HBW Insight - May 22, 2026
Weekly digest of US consumer health industry/marketplace news: Congress proposes adding supplements to HSA/FSAs; acting FDA foods program chief familiar to industry; PRE study guidance for formula industry; higher costs not new to industry; and ‘fundamental reset’ in longevity wellness.
HBW Insight - May 22, 2026
ASCO Preview: Top Five Picks From The Abstract Release
The oncology conference promises some significant data readouts across pancreatic, breast and lung cancers, lymphoma, myeloma and more.
Scrip - May 22, 2026
The oncology conference promises some significant data readouts across pancreatic, breast and lung cancers, lymphoma, myeloma and more.
Scrip - May 22, 2026
Deal Watch: Quince Moves Into Inhaled Respiratory Disease With Orphai Acquisition
Plus deals involving Incyte/Genesis Molecular AI and Edison Scientific, Jupiter/PharmAla, Abeona/Angeles Therapeutics, Daewoong/Innovo, GSK/CTTQ and more.
Scrip - May 22, 2026
Plus deals involving Incyte/Genesis Molecular AI and Edison Scientific, Jupiter/PharmAla, Abeona/Angeles Therapeutics, Daewoong/Innovo, GSK/CTTQ and more.
Scrip - May 22, 2026
Bayer Raises Its Cell And Gene Therapy Bet As Others Fold
The sector has seen multiple setbacks, with some big pharmas heading for the exits, but the German major believes its heavy investments in the space will ultimately pay dividends.
Scrip - May 22, 2026
The sector has seen multiple setbacks, with some big pharmas heading for the exits, but the German major believes its heavy investments in the space will ultimately pay dividends.
Scrip - May 22, 2026
Biogen, Denali Discontinue BIIB122 Development In Idiopathic Parkinson’s After Phase IIb Miss
Biogen and Denali’s decision to discontinue BIIB122 in idiopathic Parkinson’s disease after a failed Phase IIb study shifts focus toward genetically defined LRRK2 patient subsets and other late-stage neuroscience pipeline catalysts.
Scrip - May 22, 2026
Biogen and Denali’s decision to discontinue BIIB122 in idiopathic Parkinson’s disease after a failed Phase IIb study shifts focus toward genetically defined LRRK2 patient subsets and other late-stage neuroscience pipeline catalysts.
Scrip - May 22, 2026
The 30-Day Bet: Serum Institute Plans Rapid Response To Ebola Outbreak
As Serum Institute aims to get an Oxford-partnered vaccine out at unprecedented speed, the question is whether industry players like Serum, Mapp, Hyundai and others can move faster with vaccines or experimental drugs than Ebola’s Bundibugyo species?
Scrip - May 22, 2026
As Serum Institute aims to get an Oxford-partnered vaccine out at unprecedented speed, the question is whether industry players like Serum, Mapp, Hyundai and others can move faster with vaccines or experimental drugs than Ebola’s Bundibugyo species?
Scrip - May 22, 2026
ASCO Preview: BioNTech, Innovent/Takeda Vie For Top IO Combo Responses In 1L NSCLC
BioNTech’s pumitamig demonstrated an ORR of 77.3% in first-line NSCLC regardless of PD-L1 status, while Innovent/Takeda’s IBI363 pushed the rate to 86.4% in the non-PD-L1-high population, ASCO abstracts show.
Scrip - May 22, 2026
BioNTech’s pumitamig demonstrated an ORR of 77.3% in first-line NSCLC regardless of PD-L1 status, while Innovent/Takeda’s IBI363 pushed the rate to 86.4% in the non-PD-L1-high population, ASCO abstracts show.
Scrip - May 22, 2026
New Data Show Medtronic’s Altaviva Offers ‘Greater Flexibility’ For Treating Urge Incontinence
Medtronic presented 24-month data from its Altaviva TITAN 2 pivotal study at the 2026 American Urological Association Annual Meeting in DC. Medtronic says Altaviva, a small device implanted just below the skin near the ankle, offers relief for millions with urge urinary incontinence.
Medtech Insight - May 22, 2026
Medtronic presented 24-month data from its Altaviva TITAN 2 pivotal study at the 2026 American Urological Association Annual Meeting in DC. Medtronic says Altaviva, a small device implanted just below the skin near the ankle, offers relief for millions with urge urinary incontinence.
Medtech Insight - May 22, 2026
MiniMed Study Finds Sensor Choice Has Little Impact On Glycemic Outcomes With 780G System
A head-to-head crossover trial and real-world data from more than 20,000 patients point to the same conclusion: in automated insulin delivery, the algorithm matters more than the sensor. MiniMed's 780G system is now backed by mounting evidence – and a fresh Nasdaq listing.
Medtech Insight - May 22, 2026
A head-to-head crossover trial and real-world data from more than 20,000 patients point to the same conclusion: in automated insulin delivery, the algorithm matters more than the sensor. MiniMed's 780G system is now backed by mounting evidence – and a fresh Nasdaq listing.
Medtech Insight - May 22, 2026
Abiomed’s Latest Impella Recall Can’t Be Fixed by Swapping Units
The FDA has issued an early alert on Automated Impella Controllers from Johnson & Johnson subsidiary Abiomed because the devices may suddenly restart. This is the latest in a series of recalls for the heart pump specialists.
Medtech Insight - May 22, 2026
The FDA has issued an early alert on Automated Impella Controllers from Johnson & Johnson subsidiary Abiomed because the devices may suddenly restart. This is the latest in a series of recalls for the heart pump specialists.
Medtech Insight - May 22, 2026
EMA Decision For Boehringer’s Jascayd Paves Way For New IPF and PPF Treatment In Europe
Jascayd, for treating adults with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, is among eight new medicines that the European Medicines Agency recommended for pan-EU marketing approval this week.
Pink Sheet - May 22, 2026
Jascayd, for treating adults with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, is among eight new medicines that the European Medicines Agency recommended for pan-EU marketing approval this week.
Pink Sheet - May 22, 2026
EU Notified Bodies See A Weakened System While Industry Counts On Timeline Predictability
EU notified bodies will be given maximum turnaround times for medtech file processing once the European Commission’s binding EU implementing regulation comes into force. Notified bodies think it does not give due attention to their place in the care delivery system.
Medtech Insight - May 22, 2026
EU notified bodies will be given maximum turnaround times for medtech file processing once the European Commission’s binding EU implementing regulation comes into force. Notified bodies think it does not give due attention to their place in the care delivery system.
Medtech Insight - May 22, 2026
Personalis Wins Fourth Medicare Coverage For NeXT Personal MRD Test In Neoadjuvant Breast Cancer
Medicare will now reimburse Personalis's ultrasensitive ctDNA test for monitoring treatment response before surgery in Stage II–III triple-negative and HER2-positive breast cancer patients, extending the test's coverage footprint deeper into the treatment pathway.
Medtech Insight - May 22, 2026
Medicare will now reimburse Personalis's ultrasensitive ctDNA test for monitoring treatment response before surgery in Stage II–III triple-negative and HER2-positive breast cancer patients, extending the test's coverage footprint deeper into the treatment pathway.
Medtech Insight - May 22, 2026
MHRA Outlines Plans For Medical Device CE Mark Recognition
At RAPS 2026, the MHRA announced updates on its consultation for indefinite CE Mark recognition and its own version of breakthrough device designation.
HBW Insight - May 22, 2026
At RAPS 2026, the MHRA announced updates on its consultation for indefinite CE Mark recognition and its own version of breakthrough device designation.
HBW Insight - May 22, 2026
People On The Move: Appointments at Cooper, Opella, Chiesi
A round up of the latest people moves: Cooper Consumer Health names Italy head and Iberia marketing lead; Opella appoints people head for Europe and LatAm; and Chiesi elects chair.
HBW Insight - May 22, 2026
A round up of the latest people moves: Cooper Consumer Health names Italy head and Iberia marketing lead; Opella appoints people head for Europe and LatAm; and Chiesi elects chair.
HBW Insight - May 22, 2026
FDA Will Miss May Allergen Labeling Rule Deadline – OCC Deputy Director
Deputy Director of the US FDA's Office of Cosmetics and Colors provided a MoCRA update during IBA's Spring 2026 Cosmetics Convergence conference in New York May 21.
HBW Insight - May 22, 2026
Deputy Director of the US FDA's Office of Cosmetics and Colors provided a MoCRA update during IBA's Spring 2026 Cosmetics Convergence conference in New York May 21.
HBW Insight - May 22, 2026
US Consumer Health Industry News Digest: Business, Regulation, Science
Weekly digest of US consumer health industry/marketplace news: Congress proposes adding supplements to HSA/FSAs; acting FDA foods program chief familiar to industry; PRE study guidance for formula industry; higher costs not new to industry; and ‘fundamental reset’ in longevity wellness.
HBW Insight - May 22, 2026
Weekly digest of US consumer health industry/marketplace news: Congress proposes adding supplements to HSA/FSAs; acting FDA foods program chief familiar to industry; PRE study guidance for formula industry; higher costs not new to industry; and ‘fundamental reset’ in longevity wellness.
HBW Insight - May 22, 2026
CHMP Endorses Another Ranibizumab For Lupin
At its latest meeting, the EMA’s CHMP has endorsed a further biosimilar ranibizumab rival to Lucentis from Lupin. Meanwhile, Celltrion has withdrawn a filing for an infliximab product.
Generics Bulletin - May 22, 2026
At its latest meeting, the EMA’s CHMP has endorsed a further biosimilar ranibizumab rival to Lucentis from Lupin. Meanwhile, Celltrion has withdrawn a filing for an infliximab product.
Generics Bulletin - May 22, 2026
Formycon Launches Pre-Filled Eylea Biosimilars In Europe
With a US launch window locked in for Q4 2026 and Europe already live, Formycon is converting years of development and deal-making into commercial momentum.
Generics Bulletin - May 22, 2026
With a US launch window locked in for Q4 2026 and Europe already live, Formycon is converting years of development and deal-making into commercial momentum.
Generics Bulletin - May 22, 2026
Is AI The Catalyst For Global Biosimilars Development? IQVIA and Kexing Think So
As AI takes center stage, a new extended partnership between Kexing Biopharm and IQVIA is working to further global biosimilars development.
Generics Bulletin - May 22, 2026
As AI takes center stage, a new extended partnership between Kexing Biopharm and IQVIA is working to further global biosimilars development.
Generics Bulletin - May 22, 2026
Sawai Seeks Margin Protection Through Scale And Reliability
Sawai is positioning stable supply, new launches and expanded capacity as profit levers under Japan’s tougher generics pricing regime, even as mature products face pressure.
Generics Bulletin - May 22, 2026
Sawai is positioning stable supply, new launches and expanded capacity as profit levers under Japan’s tougher generics pricing regime, even as mature products face pressure.
Generics Bulletin - May 22, 2026
The Wonders Of The Microbiome Approach According To Freya Biosciences
Colleen Acosta, CEO and co-founder of Freya Biosciences, focuses on the success of developing microbial immunotherapies, and why industry must direct more attention to the space of women’s healthcare.
In Vivo - May 21, 2026
Colleen Acosta, CEO and co-founder of Freya Biosciences, focuses on the success of developing microbial immunotherapies, and why industry must direct more attention to the space of women’s healthcare.
In Vivo - May 21, 2026
MedTech Forum 2026: Global Trade Is No Longer Just A Question Of Economics
In 2026, the heavy hand of geopolitics, industrial policy, economic security and resilience has dictated the pace – or even the fact of – global trade in medtech, said MedTech Europe’s Diana Kanecka on a panel at the MedTech Forum 2026.
In Vivo - May 21, 2026
In 2026, the heavy hand of geopolitics, industrial policy, economic security and resilience has dictated the pace – or even the fact of – global trade in medtech, said MedTech Europe’s Diana Kanecka on a panel at the MedTech Forum 2026.
In Vivo - May 21, 2026
Jazz Digs In On Sleep And Epilepsy And Eyes What’s Next
Jazz used AAN 2026 to defend Epidiolex and Xywav with post-approval evidence, while signaling a shift toward a deeper rare-neuroscience platform beyond its two commercial brands.
In Vivo - May 21, 2026
Jazz used AAN 2026 to defend Epidiolex and Xywav with post-approval evidence, while signaling a shift toward a deeper rare-neuroscience platform beyond its two commercial brands.
In Vivo - May 21, 2026
Beyond the Blockbusters: The Next Wave of First-in-Class Oncology Mechanisms
In this article, the fourth and final instalment of the oncology therapeutic review series, In Vivo looks to the mechanisms competing to become the next frontier.
In Vivo - May 21, 2026
In this article, the fourth and final instalment of the oncology therapeutic review series, In Vivo looks to the mechanisms competing to become the next frontier.
In Vivo - May 21, 2026